EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

The Effect of Vasopressin on 90‐Day Mortality in Patients With Cardiogenic Shock: A Retrospective Cohort Study Using Propensity Score‐Weighted Analysis

Christophe Beyls iD, Thomas Hanquiez, Nicolas Mollet, Yoni Sarfati, Adel Zerima, Souheil Chafiki, Patricia Besserve, Hervé Dupont, Momar Diouf, Osama Abou-Arab, Yazine Mahjoub

Cardiovascular Therapeutics · 2025-01 · 2025 (1)

DOI: 10.1155/cdr/9920490 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 28.05.2025. Verfasst von Christophe Beyls und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France. Hauptthemen laut MEDLINE: Shock, Cardiogenic, Vasopressins, Vasoconstrictor Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiogenic shock (CS) may lead to a refractory vasoplegic state that requires vasopressin on top of norepinephrine. Vasopressin has been available in France since January 2022. However, data assessing the clinical impact of vasopressin in CS are very scarce.

Objective

In this study, we aimed to assess the association between vasopressin and 90‐day mortality in a cohort of CS.

Method

We conducted a retrospective, single‐center study at Amiens University Hospital comparing two cohorts of patients experiencing at least Stage C of CS: one historical cohort from 2018 to 2019 without vasopressin and a contemporary cohort from 2022 to 2023 treated with vasopressin. The primary outcome was 90‐day mortality. The secondary outcome was the occurrence of serious adverse events (SAEs) during ICU stay. Inverse probability of treatment weighting (IPTW) derived from propensity score was used to reduce imbalances in baseline characteristics.

Results

We included 201 patients in the study: 59 in the vasopressin group and 142 in the no vasopressin group. The SOFA score and norepinephrine equivalent were higher in the vasopressin group (13 [10–16] vs. 12 [9–15]; p = 0.02 and 0.72 [0.21–1.51] vs. 0.13 [0.07–0.34]; p < 0.001, respectively). There was no significant difference between the two groups for the 90‐day mortality ( n = 31/59 vs. 75/142; p = 0.97). Before adjustment, vasopressin was not associated with 90‐day mortality (OR = 0.98 [95% CI 0.50–1.78]; p = 0.87). After weighting, vasopressin remained not associated with 90‐day mortality (OR = 1.10 [95% CI 0.56–2.17]; p = 0.77). There was no significant difference for SAEs between the two groups ( n = 57/142 [40%] vs. n = 23/59 [39%]; p = 0.88).

Conclusion

Vasopressin was not associated with 30‐day mortality and SAEs in patients with CS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Shock, CardiogenicVasopressinsVasoconstrictor AgentsHumansRetrospective StudiesMaleFemaleAgedMiddle AgedTime FactorsPropensity ScoreTreatment OutcomeRisk FactorsRisk AssessmentAged, 80 and over

Stichwörter der Autor:innen

cardiogenic shockmortalitynorepinephrinevasopressinvasopressor

Substanzen

VasopressinsVasoconstrictor Agents

Autor:innen und Institutionen

  • Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.
  • UR UPJV 7518 SSPC (Simplification of Care of Complex Surgical Patients) Research Unit, University of Picardie Jules Verne, Amiens, France.
  • Department of Cardiology, Amiens University Hospital, Amiens, France.
  • Department of Statistics, Amiens University Hospital, Amiens, France.

ORCID-Profile: Christophe Beyls

Zitieren

APA

Beyls, C., Hanquiez, T., Mollet, N., Sarfati, Y., Zerima, A., Chafiki, S., Besserve, P., Dupont, H., Diouf, M., Abou-Arab, O., & Mahjoub, Y. (2025). The Effect of Vasopressin on 90‐Day Mortality in Patients With Cardiogenic Shock: A Retrospective Cohort Study Using Propensity Score‐Weighted Analysis. Cardiovascular Therapeutics, 2025(1). https://doi.org/10.1155/cdr/9920490

Vancouver

Beyls C, Hanquiez T, Mollet N, Sarfati Y, Zerima A, Chafiki S, et al. The Effect of Vasopressin on 90‐Day Mortality in Patients With Cardiogenic Shock: A Retrospective Cohort Study Using Propensity Score‐Weighted Analysis. Cardiovascular Therapeutics. 2025;2025(1). doi:10.1155/cdr/9920490

BibTeX
@article{Beyls2025,
  author = {Beyls, Christophe and Hanquiez, Thomas and Mollet, Nicolas and Sarfati, Yoni and Zerima, Adel and Chafiki, Souheil and Besserve, Patricia and Dupont, Hervé and Diouf, Momar and Abou-Arab, Osama and Mahjoub, Yazine},
  title = {The Effect of Vasopressin on 90‐Day Mortality in Patients With Cardiogenic Shock: A Retrospective Cohort Study Using Propensity Score‐Weighted Analysis},
  journal = {Cardiovascular Therapeutics},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/cdr/9920490}
}
Kostenlos starten →